DLEU2 participates in lymphovascular invasion and inhibits cervical cancer cell proliferation, migration, and invasion.

Autor:	Zhang H; The First School of Clinical Medicine, Lanzhou University Lanzhou 730000, Gansu, China., Wang X; The First School of Clinical Medicine, Lanzhou University Lanzhou 730000, Gansu, China.; Gansu Provincial Cancer Hospital Lanzhou 730000, Gansu, China., Zhang Q; The First School of Clinical Medicine, Lanzhou University Lanzhou 730000, Gansu, China.; Institute of Modern Physics, Chinese Academy of Sciences Lanzhou 730000, Gansu, China., Ma Y; The First School of Clinical Medicine, Lanzhou University Lanzhou 730000, Gansu, China., Wang Z; Department of Oncology, Guizhou Provincial People's Hospital Guiyang 550002, China.
Jazyk:	angličtina
Zdroj:	International journal of clinical and experimental pathology [Int J Clin Exp Pathol] 2020 Aug 01; Vol. 13 (8), pp. 2018-2026. Date of Electronic Publication: 2020 Aug 01 (Print Publication: 2020).
Abstrakt:	Aims: To investigate the roles of deleted in lymphocytic leukemia-2 (DLEU2) in the pathology of cervical cancer. Methods: Differentially expressed long non-coding RNAs between cervical cancerous and para-cancerous tissues were examined in 26 clinical specimens by microarray analysis and quantitative real-time PCR. DLEU2 expression was correlated with clinical features in 108 patients with cervical cancer. The effects of DLEU2 on growth, proliferation, migration, and invasion were examined in cervical cancer cells. Results: DLEU2 was correlated with lymphovascular invasion in patients with cervical cancer. DLEU2 overexpression inhibited cell proliferation, migration, and proliferation, and colony formation in cervical cancer cells. Conclusion: DLEU2 is involved in the pathology of cervical cancer, and it may be a target for clinical therapy. Competing Interests: None. (IJCEP Copyright © 2020.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu